New hope for pancreatic cancer? early trial combines novel drug with chemo and immunotherapy

NCT ID NCT04104672

Ongoing Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This early-phase study tests a new drug called AB680, combined with immunotherapy (zimberelimab) and two chemotherapy drugs (nab-paclitaxel and gemcitabine), in people with advanced pancreatic cancer that has spread. The main goals are to check safety and find the right dose. About 196 participants who have not had prior treatment for metastatic disease will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC CANCER

Contacts and locations

Locations

Research Site

Santa Monica, California, 90404, United States
Research Site

St Louis, Missouri, 63110, United States
Research Site

New York, New York, 10032, United States
Research Site

New York, New York, 10065, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Pittsburgh, Pennsylvania, 15232, United States
Research Site

Houston, Texas, 77030, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.